These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 19947244

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported case.
    Katodritou E, Kartsios C, Gastari V, Verrou E, Mihou D, Banti A, Lazaraki G, Lazaridou A, Kaloutsi V, Zervas K.
    Leuk Res; 2008 Feb; 32(2):339-41. PubMed ID: 17560647
    [Abstract] [Full Text] [Related]

  • 23. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A.
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [Abstract] [Full Text] [Related]

  • 24. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
    Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK.
    Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
    [Abstract] [Full Text] [Related]

  • 25. [Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
    Yuan ZG, Hou J, Zhou F, Fu WJ, Chen YB, Xi H, Yang SL.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):653-5. PubMed ID: 17343194
    [Abstract] [Full Text] [Related]

  • 26. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C.
    J BUON; 2007 Oct; 12(1):41-4. PubMed ID: 17436400
    [Abstract] [Full Text] [Related]

  • 27. [Schnitzler syndrome--report on a fourteen-year course of the disease and an overview of information on the disease].
    Adam Z, Krejcí M, Pour L, Neubauer J, Prásek J, Hájek R.
    Vnitr Lek; 2008 Dec; 54(12):1140-53. PubMed ID: 19140523
    [Abstract] [Full Text] [Related]

  • 28. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z.
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [Abstract] [Full Text] [Related]

  • 29. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
    Fukushima T, Iwao H, Nakajima A, Miki M, Sakai T, Sawaki T, Tanaka M, Masaki Y, Hirose Y, Umehara H.
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
    [Abstract] [Full Text] [Related]

  • 30. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Min CK, Lee MJ, Eom KS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Lim J, Kim Y, Han K.
    Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
    [Abstract] [Full Text] [Related]

  • 31. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    Minarik J, Scudla V, Ordeltova M, Bacovsky J, Pika T, Langova K.
    Eur J Haematol; 2009 Dec 01; 83(6):528-34. PubMed ID: 19624720
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, Kienast J.
    Leuk Res; 2005 May 01; 29(5):587-90. PubMed ID: 15755512
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H, Hayashi T, Nojima M, Yasui H, Ikeda Y, Ishida T, Adachi M, Imai K.
    Rinsho Ketsueki; 2005 Apr 01; 46(4):269-73. PubMed ID: 16444959
    [Abstract] [Full Text] [Related]

  • 36. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J.
    Br J Haematol; 2009 Mar 01; 144(6):887-94. PubMed ID: 19183191
    [Abstract] [Full Text] [Related]

  • 37. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul 01; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 38. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.
    Transplant Proc; 2009 Dec 01; 41(10):4407-10. PubMed ID: 20005409
    [Abstract] [Full Text] [Related]

  • 39. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
    Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK.
    Eur J Haematol; 2012 Nov 01; 89(5):432-4. PubMed ID: 22971164
    [No Abstract] [Full Text] [Related]

  • 40. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.
    Expert Rev Anticancer Ther; 2008 Jul 01; 8(7):1053-72. PubMed ID: 18588451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.